Keywords
How to Cite
Abstract
Inhibitors of immune control points (ICP) is a new group of drugs used to treat patients with incurable neoplasias, in particular their metastatic forms. However, there is a risk of developing immune-mediated adverse events from a number of organ systems during therapy with these drugs. Immune-mediated adverse events are understood as a side effect due to excessive activation of the immune system with autoimmune damage to normal tissues of various organs and systems, and not the main goal of immunotherapy. In particular, one of these side effects when using ICP is the development of endocrinopathies (thyroiditis, hypophysitis, adrenalitis, type 1 diabetes mellitus). We present a literature review and a clinical case of the development of hypothyroidism, hyponatremia and psychosis in a patient after nivolumab therapy for recurrent colorectal cancer 3 months after immunotherapy.
References
Эндокринология национальное руководство/под ред. Дедова И.И., Мельниченко Г.А. М.. 2013: 338-339 [In: Dedov II, Melnichenko GA, editors. Endocrinology. National guidelines. Moscow; 2011:338–339 (In Russ.)].
Фадеев В.В. Современные принципы диагностики и лечения гипотиреоза, лекции для врачей общей практики. Журнал «Земский Врач». 2010; 2: 13-16 [Fadeev V.V. Current approach to diagnosis and treatment of hypothyroidism. Journal “Zemsky vrach”. 2010;2:13-16 (in Russ.)].
Liamis G., Filippatos T.D., Liontos A. et al. Hypothyroidism-associated hyponatremia: mechanisms, implications and treatment. European Journal of Endocrinology. Bioscientifica. 2017;176(1): R15–R20. http://dx.doi.org/10.1530/EJE-16-0493.
Spasovski G., Vanholder R., Allolio B. et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrology Dialysis Transplantation [Internet]. Oxford University Press (OUP). 2014 Feb 25;29(suppl_2):i1–i39. http://dx.doi.org/10.1093/ndt/gfu040.
Багров Я.Ю. Гипонатриемия: патогенез, клиника, лечение. Нефрология и диализ. 2005;7(4):418-419 [Bagrov J.Y. Hyponatremia: pathogenesis, clinical features, treatment. Nephrology and dialysis. 2005;7(4):418-419 (In Russ.)].
Реутова Е.В., Лактионов К.П., Бредер В.В. и др. Иммуноопосредованные нежелательные явления, связанные с лечением препаратами, блокирующими контрольные точки Т-лимфоцитов. Злокачественные опухоли. 2016;20(4):68-70 [Reutova E.V., Laktionov K.P., Breder V.V. et al. Immune-mediated adverse events associated with immune checkpoint inhibitors therapy. Malignant Tumours. 2016;20(4):68-70 (in Russ.)].
Состояние онкологической помощи населению в России в 2018 г. / под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М. 2019:4. [Status of cancer assistance in the population of Russia in 2018. / in. A.D. Kaprin, V.V. Starynskiy, G.V. Petrova. Moscow. 2019: 4. (In Russ.)].
Опдиво – официальная инструкция по применению. Регистрационный номер - ЛП004026 – 221216.
Cukier P., Santini F.C., Scaranti M., Hoff A.O. Endocrine side effects of cancer immunotherapy. Endocrine-Related Cancer. Bioscientifica. 2017 Dec;24(12):T331–T347. . http://dx.doi.org/10.1530/erc-17-0358.
de F.J., Andreescu C., Cools F. et al. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Endocrine Abstracts. Bioscientifica. 2018 May 8; http://dx.doi.org/10.1530/endoabs.56.gp211.
Hellmann M.D., Rizvi N.A., Goldman J.W. et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. The Lancet Oncology. Elsevier BV. 2017 Jan;18(1):31–41. http://dx.doi.org/10.1016/s1470-2045(16)30624-6.
John V., Evans P., Kalhan A. Delayed dyskinesia and prolonged psychosis in a patient presenting with profound hyponatraemia. Endocrinology, Diabetes & Metabolism Case Reports. Bioscientifica. 2017 Mar 13;2017. http://dx.doi.org/10.1530/edm-16-0147.
González-Rodríguez E., Rodríguez-Abreu D. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. The Oncologist. Alphamed Press. 2016 Jun 15;21(7):804–16. http://dx.doi.org/10.1634/theoncologist.2015-0509.
Brahmer J.R., Lacchetti C., Thompson J.A. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. Journal of Oncology Practice. American Society of Clinical Oncology (ASCO). 2018 Apr;14(4):247–9. http://dx.doi.org/10.1200/jop.18.00005.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2020